AL
PVLA

Aspiriant LLC’s Palvella Therapeutics PVLA Stock Holding History

Aspiriant LLC’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$729K Hold
5,852
– – 0.02% 184
2025
Q4 		$613K Hold
5,852
– – 0.02% 200
2025
Q3 		$367K Buy
+5,852
New +$261K 0.01% 226

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aspiriant LLC's PVLA Position: Q1 2026 in Review

Aspiriant LLC held its Palvella Therapeutics (PVLA) position steady in Q1 2026 at 5,852 shares worth $729K. The position accounts for 0.02% of the portfolio, ranked #184.

Aspiriant LLC first reported a position in PVLA in Q3 2025 and has held it in 3 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Aspiriant LLC held 5,852 shares of Palvella Therapeutics worth $729K as of Q1 2026.
  • Aspiriant LLC left its Palvella Therapeutics share count unchanged in Q1 2026.
  • Palvella Therapeutics made up 0.02% of Aspiriant LLC's portfolio in Q1 2026, its #184 holding.
  • Aspiriant LLC first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Aspiriant LLC's 13F filing for Q1 2026, filed 12 May 2026.